Board of Directors
The Institute’s Board of Directors is responsible for the overall governance of the Institute, including its strategic direction, risk management and monitoring of financial and other reporting.
Michael J. Hawker AM
Michael Hawker is a Non-Executive Director of Aviva Plc Group (UK), the Macquarie Group Limited, Macquarie Bank Limited and Washington H. Soul Pattinson. Michael is Chair of the Australian Business and Community Network Foundation, a Non-Executive Director of the Rugby World Cup Limited. His former Executive roles include Chair of the Australian Rugby Union, Non-Executive Director of SANZAR Pty Limited, Member of the Executive Committee, World Rugby Council, CEO and Managing Director of Insurance Australia Group, Group Executive of Business and Consumer Banking at Westpac, Executive Director of Citibank International in Europe, and a Deputy Managing Director of Citibank in Australia. He has been President of the Insurance Council of Australia and the Australian Financial Markets Association, a former Board member of The Geneva Association and a former member of the Financial Sector Advisory Council. He is a Senior Fellow of the Financial Services Institute of Australia and a Fellow of the Australian Institute of Company Directors. Michael joined the Board in February 2011.
Russell Aboud has worked in the global investment industry both domestically and internationally for over 29 years, the majority of time as a Managing Director in Sydney and London for UBS. Currently, Russell is the Executive Chairman and a founding partner of Manikay Partners, a New York-based multi-strategy global investment firm. Former appointments include Non-Executive Director of the Australian Securities Exchange, Chairman of Ord Minnett and Senior Advisor to JP Morgan Australia. Russell joined the Board in August 2013.
Yasmin Allen is a non-executive director of Cochlear Limited, Chairman of its Audit Committee and a member of Cochlear’s technology committee. She is also a non-executive director of ASX Limited, member of the ASX Audit Committee and ASX Clearing and Settlement board. Yasmin is a director at Santos Limited and a member of Santos’ Remuneration Committee and Environment, Health and Saftey Committee. She is also a director of the National Portrait Gallery.
Yasmin's previous directorships include Insurance Australia Group Limited (IAG) where she was Chairman of IAG’s Nomination and Remuneration Committee and a member of its Audit and Risk Committee. Yasmin was also Chairman of Macquarie Global Infrastructure Funds and a National Director of the Australian Institute of Company Directors.
Prior to her directorships, Yasmin had an extensive career in investment banking, including as Vice President of Deutsche Bank, Director of ANZ Investment Bank in Sydney and Director with HSBC in London. She has a Bachelor of Commerce from Melbourne University and in 2015 was awarded their Alumni of Distinction Award. She is a Fellow of the Australia Institute of Company Directors and a member (and former council member) of Chief Executive Women. Yasmin joined the board in August 2014.
Gina Anderson is an experienced company Director. She is currently a Non-Executive Director of GDI Property Group and GDI Funds Management; Advisory Board Member of the Australian Charities and Not-for-profits Commission (ACNC); Co-Founder and Chair of Women's Community Shelters; Advisory Board Member, Initiative on Corporate Philanthropy, The Conference Board, USA; and Philanthropy Fellow, Centre for Social Impact, University of NSW. Gina was Executive Director and CEO of Philanthropy Australia from 2005 to 2010. She has held corporate affairs, human resources and general management roles, including seven years in senior management roles at Westpac. From 1992-1995 as personal assistant to the Crown Prince of Jordan she was involved in the peace treaty between Jordan and Israel. Gina joined the Board in February 2012, and is Chair of its Development Committee.
David Armstrong is a Non-Executive Director of the National Australia Bank (since August 2014). Chair of the Risk Committee and a member of its Audit Committee and Information Technology Committee. David is also a Director of the Opera Australia Capital Fund Limited (since May 2013), and a Trustee of the Australian Museum (since January 2014) and Lizard Island Reef Research Foundation (since April 2014). David has more than 30 years’ experience in professional services. As a Chartered Accountant and a former partner of PricewaterhouseCoopers, he has significant knowledge and understanding of banking and capital markets, real estate and infrastructure and is well versed in reporting, regulatory and risk challenges faced by the industry. David has lived and worked in London and New York at various stages of his career. David is a Fellow of the Institute of Chartered Accountants in Australia and a member of the Australian Institute of Company Directors. David joined the Board in October 2014, and is Chair of its Finance, Risk and Audit Committee.
Catherine Livingstone AO
Catherine Livingstone spent 20 years working in the field of implantable medical devices, including six years as CEO and Managing Director of Cochlear Limited. She is a Non-Executive Director of Commonwealth Bank Australia Limited and a Non-Executive Director of Worley Parsons Limited and Saluda Medical Pty Ltd. She is President of the Business Council of Australia, a member of the Commonwealth Science Council, the Growth Centres Advisory Committee; and is President of the Australian Museum. Catherine’s former roles include Chairman of Telstra Corporation Limited, Chair of the Commonwealth Scientific and Industrial Research Organisation (CSIRO), President of Chief Executive Women, Chair of The Australian Business Foundation, Non-Executive Director of the Macquarie Group; and a Member of the New South Wales Innovation and Productivity Council. Catherine joined the Board in August 2012.
Paul McClintock AO
Paul McClintock is Chairman of Myer Holdings Limited, NSW Ports, I-MED Network, Sydney Health Partners, the Committee for Economic Development of Australia, and a Director of St Vincent’s Health Australia Limited. Paul has served as the Secretary to Cabinet and Head of the Cabinet Policy Unit reporting directly to the Prime Minister as Chairman of Cabinet, supervising Cabinet processes and acting as the Prime Minister’s most senior personal policy adviser. Former positions include Chairman of Medibank Private Limited, Thales Australia, the COAG Reform Council, Intoll Management Limited, Symbion Health, Affinity Health, Ashton Mining, Plutonic Resources and the Woolcock Institute of Medical Research. Paul graduated in Arts and Law from the University of Sydney and is an Honorary Fellow of the Faculty of Medicine. Paul joined the Board in October 2013.
Melinda Conrad is currently a Non-Executive Director of ASX Limited, OFX Group Limited (Chair of its Remuneration Committee and Member of its Audit and Risk Committee), and The Reject Shop Limited (Chair of its Remuneration Committee and Member of its Audit and Risk Committee). Melinda is also a Director of the Centre for Independent Studies, Member of the Minter Ellison Advisory Board and Member of the Australian Institute of Company Directors Corporate Governance Committee.
Melinda has also served as Non-Executive Director of David Jones Limited, APN News & Media Limited, NSW Clinical Excellence Commission, NSW Agency for Clinical Innovation, and the Garvan Medical Research Institute Foundation. Melinda a Fellow of the Australian Institute of Company Directors. Melinda joined the Board November 2015.
Dr Srinivas Akkaraju
Srinivas Akkaraju is a former General Partner of Sofinnova Ventures. Prior to Sofinnova, Srini was a Managing Director of New Leaf Venture Partners, and prior to that, a Founding Managing Director at Panorama Capital, LLC., a prior to that, a Partner with J.P. Morgan Partners. Before his investment career, he was in Business and Corporate Development at Genentech, Inc. (now a wholly owned member of The Roche Group), a biotechnology company, most recently as Senior Manager. Dr Akkaraju currently serves as a Director of Intercept Pharmaceuticals, Inc., Seattle Genetics, Versartis Inc., and aTyr Pharma, Inc. Previously, Dr. Akkaraju served as a director on the boards of ZS Pharma, Inc., Eyetech Pharmaceuticals, Inc., Synageva Biopharma Corp., Barrier Therapeutics, Inc., and Amarin Corporation plc. Srinivas joined the Board February 2016.
David Baffsky AO
David Baffsky AO holds a law degree from the University of Sydney and was the founder, and until 1991, the senior partner of a Sydney legal firm specialising in commercial and fiscal law. David is Honorary Chairman (formerly Executive Chairman between 1993 and 2008) of Accor Asia Pacific, which is the largest hotel management company in the Asia Pacific region. He is Chairman of the ASX listed Ariadne Australia Ltd and Chairman of Investa Property Group. He is also on the boards of Sydney Olympic Park Authority, Destination NSW and the Australian Brandenburg Orchestra. He was until July 2016 a Director of SATS Limited (Singapore) and Chairman of Food & Allied Support Services Corporation Ltd.
Amongst previous roles, Mr Baffsky was a Trustee of the Art Gallery of NSW, Chairman of Voyages Indigenous Tourism Ltd, a member of the Business Government Advisory Group on National Security. He was a member of the federal government’s Northern Australia Land and Water Taskforce and a Director of the Indigenous Land Corporation. In 2001 Mr Baffsky was made an officer in the General Division of the Order of Australia and in 2003 he received the Centenary Medal. In 2004 he was recognised as the Asia Pacific Hotelier of the Year. In 2012 he was awarded the Chevalier in the Order of National Légion d’Honneur of France.
Professor Robyn Norton
Robyn Norton is co-founder and Principal Director of The George Institute for Global Health. She is Professor of Global Health & Oxford Martin Senior Fellow, University of Oxford; Professor of Public Health, Faculty of Medicine, UNSW Sydney; and Honorary Professor at Peking University.
Professor Norton has published widely and is internationally regarded for her research on the causes, prevention and management of injuries, especially road traffic and fall-related injuries, as well as the management of various critical conditions in surgical and intensive care settings. She was the inaugural Chair and is now Chair Emeritus of the Road Traffic Injuries Research Network, a network supported by the World Bank and the WHO, aimed at building research capacity and research agendas, to address the growing burden of road traffic injuries in low and middle income countries.
She has had a long-standing commitment to improving women’s health and currently leads The George Institute’s research, implementation and advocacy efforts, aimed at improving the health of women and girls worldwide. Most recently she was the lead author on a University of Oxford supported policy paper entitled “Women’s Health: A New Global Agenda”, calling for a greater focus on addressing the burden of non-communicable diseases in women and the importance of a gendered approach to the collection and utilisation of health data.
此外，Robyn教授长期致力于改善妇女健康，她是《妇女健康: 全新全球议程(Women’s Health: A New Global Agenda)》政策文件的主要作者。报告由英国牛津大学发布，其目的是提高慢性病防控在妇女健康议程中的比重，并且呼吁使用性别分类方法来实施健康数据分析，从医疗卫生角度减少性别不平等。作为推动妇女健康议程全球对话的系列报告开篇之作，最终目标是通过驱使政策转变以挽救更多生命。
Professor Stephen MacMahon
Stephen is one of the founders of The George Institute for Global Health, an architect of its global expansion and currently holds the position of Principal Director of The George Institute for Global Health (worldwide).
He also holds professorial appointments in medicine at UNSW Sydney and the University of Oxford (UK), where he is a Oxford Martin Senior Fellow. Stephen is an international authority on the causes, prevention and treatment of cardiovascular diseases and has a special interest is the management of chronic and complex conditions in resource-poor settings, particularly in the Asia-Pacific region.
In addition to his Institute and university appointments, Stephen has held several external appointments, including former Chair of the International Scientific Board of the UK BioBank. He is also Executive Chair of George Clinical Pty Ltd, a wholly owned subsidiary of The George Institute. He sits on the Boards of several other not-for-profit organisations, including the Oxford Health Alliance.
Stephen has published more than 300 scientific papers and delivered more than 200 invited lectures. For his work in the field of cardiovascular disease, he has received numerous awards, fellowships and honours from various governments, universities and learned societies.